Please use this identifier to cite or link to this item:
|Title:||Triple negative breast cancer: nanosolutions for a big challenge|
Rodrigues, L. R.
triple negative breast cancer (TNBC)
|Citation:||Mendes, T.; Kluskens, Leon; Rodrigues, L. R., Triple negative breast cancer: nanosolutions for a big challenge. Advanced Science, 2(11), 1-14, 2015|
|Abstract(s):||Triple negative breast cancer (TNBC) is a particular immunopathological subtype of breast cancer that lacks expression of estrogen and progesterone receptors (ER/PR) and amplification of the human epidermal growth factor receptor 2 (HER2) gene. Characterized by aggressive and metastatic phenotypes and high rates of relapse, TNBC is the only breast cancer subgroup still lacking effective therapeutic options, thus presenting the worst prognosis. The development of targeted therapies, as well as early diagnosis methods, is vital to ensure an adequate and timely therapeutic intervention in patients with TNBC. This review intends to discuss potentially emerging approaches for the diagnosis and treatment of TNBC patients, with a special focus on nano-based solutions that actively target these particular tumors.|
|Appears in Collections:||CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series|